RestorCel® is the proprietary, clinically studied blend powering Cartigenix HP®. RestorCel is backed by three published human studies covering more than 1,600 participants across prospective, observational, and randomized controlled study designs. In the double-blind, placebo-controlled trial, participants showed a 64% average reduction in WOMAC pain scale scores, a 50% increase in walking distance at 90 days, and significant improvements in cartilage regeneration biomarkers.*† Across all three studies, Cartigenix HP with RestorCel produced a 67% average reduction in pain scores at 90 days.*
What Is RestorCel?
RestorCel is a standardized and patented blend of 13 bioactive compounds, including serratol from Boswellia serrata and a standardized North India celery seed extract. The bioactives were selected for their synergistic ability to support cartilage regeneration, joint comfort, and mobility.*
A key methodological point for evaluating this evidence: the complete, finished Cartigenix HP formulation (RestorCel) was evaluated in all three published studies, not individual ingredients tested in isolation.
The Three Published Human Studies
| Study | Design | Participants | Key Outcome |
|---|---|---|---|
| Desai 2022 | Prospective | 1,236 | 72.5% improvement in WOMAC pain scores* |
| Desai 2024 | Observational | 394 | 75% improvement in pain scores; 79% improvement in function scores* |
| Vaidya 2025 | Randomized, placebo-controlled | 62 | 64% WOMAC pain score reduction; 50% walking distance gain; increase in cartilage regeneration biomarkers* |
The Vaidya 2025 randomized, placebo-controlled trial, published in Pharmaceutical Research, is the controlled-design study in the RestorCel evidence base. Over 90 days, participants showed a 64% average reduction in WOMAC pain scale scores, a validated clinical outcome tool that captures joint discomfort across standardized domains, a 50% increase in walking distance, measured via the six-minute walk test, and statistically significant improvements in cartilage regeneration biomarkers.*†
†As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores, along with quality of life measures (Desai 2022).
Explore a more robust review of research on cartilage regeneration and joint health here.
Cartilage Regeneration Biomarkers: What PIIANP and PIICP Measure
The Vaidya 2025 study measured cartilage regeneration biomarkers PIIANP and PIICP, at baseline and at 90 days. PIIANP and PIICP are objective biological signals that cartilage is regenerating at the tissue level, and are distinct from participant-reported comfort measures.† Because many joint health supplement trials rely solely on participant-reported measures, the inclusion of biomarker data alongside those measures gives practitioners two distinct types of evidence rather than one.*†
As one Calroy educator, Tom Bayne, DC, has noted, the addition of tissue-level biomarker data alongside participant-reported outcomes represents a meaningful shift for a category that has historically had little more than anecdotal support to offer.
How RestorCel Compares to Legacy Joint Health Ingredients
The category's dominant ingredients for decades, glucosamine and chondroitin, show little or inconsistent effects in terms of comfort compared to the placebo in multiple meta analyses. Across the three published studies on RestorCel, pain scores were reduced by an average of 67%. Additionally, RestorCel's research profile includes an objective tissue-level biomarker finding not documented for glucosamine and chondroitin in the same evidence base.*†
See a side-by-side comparison of Cartigenix HP and glucosamine and chondroitin. A more in-depth, clinician version of this chart for healthcare providers is available in the Practitioner Education Hub.
General research on cartilage health can be accessed here.
Timeline and Long-Term Use
Participants reported noticeable changes in joint comfort and flexibility as early as 15 days, with significant outcomes documented at 90 days.*† No adverse events were reported across any of the three published human studies, and none have been reported to Calroy Health Sciences since. The Cartigenix HP formulation is vegan, non-GMO, and free from gluten, dairy, and soy. Individuals with specific medical conditions or taking prescription medications should consult their healthcare provider before beginning any supplement.
The Connection to Cartigenix HP
RestorCel is the core of the Cartigenix HP formula. It is a proprietary blend of 13 bioactives compounds. These include serratol from Boswellia serrata and a standardized North India celery seed extract, selected for their synergistic ability to support cartilage regeneration, joint comfort, and healthy mobility, in just one capsule twice a day.*
For the full clinical picture, see The 2026 Clinician's Guide: Can Cartilage Really Regenerate with Supplements? and Cartilage Regeneration with Joint Supplements: What a Placebo-Controlled Study Showed Beyond Pain Scores.
A downloadable PDF version of this summary is available for practitioners in the Practitioner Education Hub.
Frequently Asked Questions
Is there an evidence summary or clinician deck available for RestorCel? Yes. RestorCel is backed by three published human studies covering more than 1,600 participants. This page summarizes the study designs, key outcomes, and biomarker findings, and is available as a downloadable PDF for practitioners through the Practitioner Education Hub.
Individuals looking for general research on joint health and cartilage can find it here.
What is RestorCel and what does it contain? RestorCel is the proprietary blend powering Cartigenix HP. RestorCel contains 13 bioactive compounds, including serratol from Boswellia serrata and a standardized North India celery seed extract. These bioactive compounds were selected for their synergistic ability to support cartilage regeneration, joint comfort, and healthy mobility.*
What are cartilage regeneration biomarkers, and why do they matter? Cartilage regeneration biomarkers, including PIIANP and PIICP, are objective biomarkers that detect activity at the tissue level, distinct from participant-reported comfort and mobility outcomes. Their inclusion in the RestorCel evidence base is uncommon in the joint health supplement category.*†
Is Cartigenix HP with RestorCel appropriate for long-term use? Yes. No adverse events were reported across any of the three published human studies. Individuals with specific medical conditions or taking prescription medications should consult their healthcare provider before beginning any supplement.
† As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores, along with quality of life measures (Desai 2022).
